Adding a new medication to existing liver cancer treatments for advanced cases

Plain-English translation of NCT07639138 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing , a medication that works to boost your immune system and stop tumor blood vessel growth, when combined with the and immunotherapy you're already taking. Researchers want to see if adding can help people with advanced liver cancer whose disease has started growing again despite previous treatments. This study includes 32 patients and aims to measure both how well the medication works and how safe it is.

Many people with advanced liver cancer eventually stop responding to the standard treatments available today. Right now, doctors don't have a clear next step for these patients. This trial exists to test whether this medication could be an effective option for people in this difficult situation.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with advanced liver cancer that cannot be surgically removed
you have received at least two previous lines of systemic treatment, including both targeted therapy and immunotherapy
your most recent treatment helped you (you had a complete response, partial response, or stable disease for at least 4 weeks) before your cancer started growing again
you have at least one measurable tumor that can be tracked on imaging
you are in good enough overall health to tolerate additional treatment (ECOG performance status 0-1)

You likely don't qualify if…

your cancer grew very quickly (within 6 weeks) on your most recent treatment without any initial benefit
you have ever taken lenalidomide before or had a severe allergic reaction to it or similar medications
you have severe, uncontrolled liver problems such as fluid buildup in your abdomen, brain dysfunction from liver disease, or active bleeding
you are pregnant, breastfeeding, or unable to use effective birth control
you have active, serious infections including uncontrolled hepatitis B or tuberculosis

What participation looks like

You will continue taking the and immunotherapy you're already on, and add the new medication to your regimen. You'll stay in the study until your cancer progresses again, you experience unacceptable side effects, or you decide to stop. The trial will monitor how long you go without your cancer getting worse and track any side effects you experience to determine if this combination approach is safe and helpful.

AI-generated summary from trial data · Jun 24, 2026 · Not medical advice

Adding a new medication to existing liver cancer treatments for advanced cases

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)